Zealand Pharma A/S
Zealand announces an amendment to its Articles of Association to reflect grant of warrants

Zealand Pharma A/S 

25.03.2015 14:05

Dissemination of a Adhoc News, transmitted by DGAP - a service of EQS Group
AG.
The issuer is solely responsible for the content of this announcement.

---------------------------------------------------------------------------

Copenhagen, 2015-03-25 14:05 CET (GLOBE NEWSWIRE) -- 25 March 2015  ─ Zealand
Pharma ('Zealand') (Nasdaq Copenhagen: ZEAL) announces an amendment to its
Articles of Association to reflect grant of warrants to Torsten Hoffmann,
former Senior Vice President and Chief Scientific Officer, as announced in
Company Announcement no. 11/2015 on 25 March 2015. 

The amendment of Zealand's Articles of Association entailed by the grant of
warrants has today been registered with the Danish Business Authority. The new
Articles of Association are attached to this announcement and are also
available on the company's website: www.zealandpharma.com. 

                                      ●●●●●



For further information, please contact:

Britt Meelby Jensen, President and Chief Executive Officer

Tel: +45 51 67 61 28, email: bmj@zealandpharma.com

Hanne Leth Hillman, Senior Vice President for Communications and Investor
Relations 

Tel: +45 50 60 36 89, email: hlh@zealandpharma.com



About Zealand Pharma

Zealand Pharma A/S ('Zealand') (Nasdaq Copenhagen: ZEAL) is a biotechnology
company based in Copenhagen, Denmark. Zealand has leading expertise in the
discovery, design and development of novel peptide medicines and possesses
in-house competences in clinical trial design and management with a therapeutic
focus on metabolic diseases and acute care indications. The company is
advancing a pipeline of novel wholly-owned medicines alongside a partnered
product and development portfolio. 

Zealand's first invented medicine, lixisenatide, a once-daily prandial GLP-1
agonist for the treatment of Type 2 diabetes, is marketed globally (ex-US) as
Lyxumia(R) and in Phase III development as a single-injection combination with
Lantus(R) (LixiLan), both under a global license agreement with Sanofi. US
regulatory submission of Lyxumia(R) is planned for Q3 2015 and US/EU regulatory
submissions for LixiLan in Q4 2015. 

Zealand's wholly-owned products include danegaptide (prevention of Ischemic
Reperfusion Injury) in Phase II and the stable glucagon product, ZP4207
(treatment of severe hypoglycemia) in Phase I as well as several preclinical
peptide therapeutics. Partnering represents an important component of strategy
to leverage in-house expertise, share development risk in large clinical
trials, provide funding and commercialize the company's products. Zealand
currently has global license agreements and partnerships with Sanofi, Helsinn
Healthcare, Boehringer Ingelheim and Eli Lilly. 

For further information: www.zealandpharma.com     Follow us on Twitter
@ZealandPharma
News Source: NASDAQ OMX



25.03.2015 The DGAP Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de

---------------------------------------------------------------------------
 
Language:     English
Company:      Zealand Pharma A/S
              
               
              Denmark
Phone:        
Fax:          
E-mail:       
Internet:     
ISIN:         DK0060257814
WKN:          
 
End of Announcement                             DGAP News-Service
 
---------------------------------------------------------------------------